Brief: Otsuka And Lundbeck Announce U.S. FDA Acceptance And Priority Review Of sNDA For Brexpiprazole For Treatment Of Agitation Associated With Alzheimer's Dementia

H Lundbeck A/S

07/01/2023 14:45

Jan 7 (Reuters) - Otsuka Corp  4768.T :
    * OTSUKA AND LUNDBECK ANNOUNCE U.S. FDA ACCEPTANCE AND
PRIORITY
REVIEW OF SNDA FOR BREXPIPRAZOLE FOR TREATMENT OF AGITATION
ASSOCIATED WITH ALZHEIMER'S DEMENTIA

Source text for Eikon:  ID:nBwc24ww8a 
Further company coverage:  4768.T 
 ((Reuters.Briefs@thomsonreuters.com;))